Filing Flows › Mereo BioPharma Group (MREO) › Q3 2026
Mereo BioPharma Group (MREO) Q3 2026 earnings results (third quarter 2026)
10-Q filed Nov 9, 2026
Mereo BioPharma Group (MREO) reported revenue of $800K for the third quarter 2026 (Q3 2026). Operating margin was -777.2%, net loss $5.9M (732.9% of revenue).
Mereo BioPharma Group, Q3 2026: revenue $800K, operating margin -777.2%, net loss $5.9M, operating cash flow −$4.1M. The chart follows the revenue to costs, profit and cash.
| Q3 2026 | Amount | Q/Q | Y/Y |
|---|---|---|---|
| Revenue | $800K | — | — |
| Operating profit | −$6.2M | — | — |
| Net earnings | −$5.9M | — | — |
| Operating cash flow | −$4.1M | — | — |
What changed
Revenue was $800K in Q3 2026.
Operating costs exceeded revenue by $6.2M, an operating margin of -777.2%. The quarter ended with a net loss of $5.9M.
Operating cash flow was −$4.1M. Non-cash charges added back $159K of depreciation and amortization and $909K of share-based compensation. Working capital and other items added $744K.
Questions
What was Mereo BioPharma Group's revenue in the third quarter 2026?
Mereo BioPharma Group (MREO) reported revenue of $800K for the third quarter 2026 (Q3 2026).
Was Mereo BioPharma Group profitable in the third quarter 2026?
Operating loss was $6.2M (-777.2% of revenue) and net loss $5.9M.